LUCIUS 卢修斯 比美替尼 Binimetinib黑色素瘤

比美替尼

美国FDA批准上市产品,疗效确切
卢修斯制药(老挝)有限公司出品

Binimetinib

老挝国家食药监局批准上市
老挝国家药检所检测认证

Composition:
Each film.coated tablet contains

LUCIUS

黑色素瘤

Binimatink

15mg

PHARMACEUTICALS

LuciBitim is a kinase inhibitor idicated. in
comoination with Encorafenib, for the treatmen
ot patients with unresectable or metastatic
melanoma with a BKAF V600E or V600K
andn, as detected bv an FDA-anoroved ted
Dosage and Use:

LuciBinim

.Contirm the presence of BRAF V600E or V600K
of1 ppcs prior to the initiation
"The recommended dose is 45 mg orally twi

Binimetinib Tablets

daily in combination with Encoralenib. Take

FDA批准

LuciBinim with or withont food

.For patients with moderate or severe nepane
impairment the recommended dose is 30 mg orally

Rx only

Storage: in a dry place and store at 20℃ to25
Waraing
Keep medicine out of reach of Children. Do no
etor LuciBinim during Pregnancy and
Lactation.

PLEASE SEE PACKAGE INSERT
Matufactured and Marketed by:
LUCIUS

权威认证

Thongmang village, Xaythany dislrici
Vientiane Capital, Laos
www.ucjus.la
Warnine: Tobe sold bu reil An
of registered physicians only, and as directe
by the ohysieuan

180 Tablets

口碑质量

适应症:
比美替尼是一种激酶抑制剂,与恩考芬尼联合用于治
疗经FDA批准的检测方法检出BRAF V600E或V600K
突变的不可切除或转移性黑色素瘤患者。
推荐剂量:
1、每日两次,每次45mg:与恩考芬尼联合使用。比美
替尼可与食物一起服用或单独服用。
2、对于中度或重度肝功能不全的患者,推荐剂量为每
日口服两次,每次30mg。